Epigenetics in CKD & CVD: A potential breakthrough therapy?
CME accredited satellite symposium to be held during ERA-EDTA 2018Agenda - May 25, 2018 - ERA EDTA, Copenhagen, Denmark
If you are attending ERA-EDTA 2018 in Copenhagen, Denmark, you are cordially invited to attend this CME accredited satellite symposium
The educational objectives of the symposium are to:
- Summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- Understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
- Review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
- Update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
Friday, May 25, 2018: 13:45 – 14:45 hrs
- Introduction, Vincent M Brandenburg, MD, University Hospital RWTH Aachen, Germany
- Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics, Erik Stroes, MD, Academic Medical Centre, Amsterdam, The Netherlands
- Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD, Louise Nordfors, MD, Karolinska Institute, Stockholm, Sweden
- A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives, Kamyar Kalantar-Zade, MD, UC Irvine School of Medicine, Irvine, Ca, USA
- Discussion & summary, All faculty
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
Supported by an unrestricted educational grant from Resverlogix